NYMC Faculty Publications

Andexanet Alfa Therapy Showed No Increased Rate of Thromboembolic Events in Spontaneous Intracranial Hemorrhage Patients: A Multicenter Electronic Health Record Study

Author Type(s)

Student, Faculty

DOI

10.1016/j.wnsx.2024.100367

Journal Title

World Neurosurgery: X

First Page

100367

Document Type

Article

Publication Date

7-1-2024

Department

Neurology

Abstract

•Intracranial hemorrhage accounts for two out of every three major intracranial hemorrhages.•Systemic anticoagulation is routinely prescribed for prevention of cerebrovascular accidents.•The FDA approved Andexanet alfa to treat life-threatening bleeding.•Andexanet alfa relationship to outcomes requires further investigation.

Share

COinS